Lupus News

Most new organ damage in systemic lupus erythematosus occurs in the first year after diagnosis, with the greatest impacts reported in the cardiovascular and musculoskeletal systems, according to data published in Lupus Science & Medicine.

Practicing shared decision-making increases overall trust in health care providers among patients with systemic lupus erythematosus, according to data published in Arthritis Care & Research.

The FDA has granted fast track designation to CB-010, an allogeneic anti-CD19 CAR T-cell therapy from Caribou Biosciences, for refractory systemic lupus erythematosus ahead of a planned phase 1 trial, according to a press release.

Patients who received an mRNA COVID-19 vaccine demonstrated a 1.16-fold higher long-term risk for systemic lupus erythematosus, while a booster was linked to higher risk for psoriasis and rheumatoid arthritis, according to data.

Women who consume the greatest daily amount of ultraprocessed foods on average demonstrate a 56% higher risk for systemic lupus erythematosus, according to data published in Arthritis Care & Research.

Long-term exposure to air pollutants, including particulate matter, increases the risk for developing systemic lupus erythematosus, according to data published in Arthritis & Rheumatology.

In September 2022, the FDA approved deucravacitinib for moderate-to-severe plaque psoriasis, officially introducing tyrosine kinase 2 inhibition to clinics across the United States.

Infections account for most in-hospital mortality in childhood systemic lupus erythematosus, with patients exhibiting lupus nephritis or end-stage renal disease at increased risk, according to data published in The Journal of Rheumatology.

The FDA has approved an investigational new drug application for Eque-cel, an autologous T-cell injection, in patients with systemic lupus erythematosus and lupus nephritis, according to a press release from the manufacturer.